Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis.

This is a Phase 2a, single arm, two-stage study in subjects with moderate to severe
ulcerative colitis. Subjects will receive 500 mg of PF-06480605 intravenously every 2 weeks
for a total of 7 doses. Blood, stool, and tissue samples will be collected at various time
points throughout the study to evaluate safety, tolerability, efficacy, pharmacokinetics, and
immunogenicity. Duration of participation for subjects will be approximately 8 months.

Inclusion Criteria:

- Male or female subjects between ≥ 18 and ≤ 75 years of age at the time of informed
consent

- Male subjects able to father children and female subjects of childbearing potential
must agree to use two highly effective methods of contraception throughout the study
and until the Week 26 visit

- Diagnosis of ulcerative colitis for ≥ 4 months

- Subjects with moderate to severe active ulcerative colitis as defined by screening
colonoscopy with total Mayo score of ≥ 6, with rectal bleeding subscore of ≥ 1, and an
endoscopic subscore of ≥ 2 on the Mayo

- Active disease beyond the rectum (> 15 cm of active disease at the screening
colonoscopy)

- Must have inadequate response to, loss of response to, or intolerance to at least one
conventional therapy for ulcerative colitis such as: Steroids; Immunosuppressants
(AZA, 6-MP, or MTX); Anti -TNF inhibitors (eg, infliximab, adalimumab, or golimumab);
Anti-integrin inhibitors (eg, vedolizumab).

- Subjects currently receiving the following treatment are eligible provided they have
been on stable doses of Oral 5-ASA or sulfasalazine for at least 4 weeks prior to
baseline; oral corticosteroids stable dose for at least 2 weeks prior to baseline;
6-MP or AZA stable dose for 8 weeks prior to baseline.

Exclusion Criteria:

- Diagnosis of indeterminate colitis, ischemic colitis, radiation colitis, diverticular
disease associated with colitis, microscopic colitis or Crohn's Disease. Subjects with
clinical findings suggestive of Crohn's disease (eg, fistulae, granulomas on biopsy)
are also excluded.

- Subjects with colonic dysplasia or neoplasia, toxic megacolon, primary sclerosing
cholangitis, known colonic stricture, history of colonic or small bowel stoma, history
of colonic or small bowel obstruction or resection

- Presence of active enteric infections (positive stool culture and sensitivity)

- Known history of HIV based on documented history with positive serological test, or
positive HIV serologic test at screening

- Presence of a transplanted organ

- Cancer or history of cancer or lymphoproliferative disease within the previous 5 years
(other than resected cutaneous basal cell or squamous cell carcinoma that has been
treated with no evidence of recurrence);

- Acute coronary syndrome (eg., myocardial infarction, unstable angina pectoris);

- Any history of cerebrovascular disease within 24 weeks before screening;

- Subject with current or a history of QT prolongation

- Class III or Class IV heart failure

- Prior evidence of liver injury or toxicity due to methotrexate

- Abnormality in hematology and/or chemistry profiles during screening (as detailed in
the protocol)

- Subjects receiving the following therapies within the designated time period:

- > 9 mg/day of oral budesonide or >20 mg/day prednisone or equivalent within 2
weeks prior to baseline

- IV, IM (parenteral), or topical (rectal) treatment of 5-ASA or corticosteroid
enemas/suppositories within 2 weeks prior to baseline

- Biologics including anti-TNF inhibitors as described: Infliximab, Adalimumab, or
Golimumab within 8 weeks prior to baseline

- Anti-integrin inhibitors (eg, vedolizumab) within 12 weeks prior to baseline

- Other investigational procedures or products, or live attenuated vaccine within
30 days prior to baseline.

- Current or history (within 2 years) of serious psychiatric disease or alcohol or drug
abuse